Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Shares Outstanding (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 13 years of Shares Outstanding data on record, last reported at $243.1 million in Q4 2025.

  • For Q4 2025, Shares Outstanding rose 10.3% year-over-year to $243.1 million; the TTM value through Dec 2025 reached $243.1 million, up 10.3%, while the annual FY2025 figure was $243.1 million, 10.3% up from the prior year.
  • Shares Outstanding reached $243.1 million in Q4 2025 per LCTX's latest filing, up from $230.3 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $243.1 million in Q4 2025 and bottomed at $162.1 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $188.9 million, with a median of $175.0 million recorded in 2023.
  • Peak YoY movement for Shares Outstanding: grew 0.26% in 2023, then grew 25.96% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $168.5 million in 2021, then rose by 0.97% to $170.1 million in 2022, then grew by 2.88% to $175.0 million in 2023, then rose by 25.96% to $220.4 million in 2024, then grew by 10.3% to $243.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding were $243.1 million in Q4 2025, $230.3 million in Q3 2025, and $228.4 million in Q2 2025.